Honestly with CHM's CAR-NK it honestly depends on their development strategy, if they decide to go solid tumors first and will most likely experience failed results then go to hematological tumors, that would be a non-investor-friendly development pathway.
But considering that CHM's CAR-NK is more within Nkarta's generation of CAR-NKs, it would most likely suffer the same durability issues a normal off-the-shelf cell therapy would go through because the body's immune system will destroy after the first dosing, and what would result is a lower response after every subsequent dose. This will limit efficacy and durability rates and will affect approvals of this line of therapies.
CRISPR-CAR-NK's tend to put inhibitors on immune system checkpoints to inhibit the immune system from attacking the CAR-NK.
Again speculative and both haven't been to the clinic, but I think I will trust the better tech.
CHM Price at posting:
10.0¢ Sentiment: Sell Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)